Physician profile
Steven Andrew Murphy
NPI 1962623165
$2,395.71
in general payments reported to CMS, 2019-2025
31 companies · $772 in 2025
The $772 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $124 · 2021: $313 · 2022: $119 · 2023: $127 · 2024: $41.55 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $638 · Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $638.00 |
| Food and Beverage | $302.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cepheid | $638.00 | 2025 | Genexpert |
| Csl Behring | $295.66 | 2020-2025 | Hizentra |
| Abbvie INC. | $197.84 | 2021-2023 | |
| Novo Nordisk INC | $132.53 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $116.37 | 2019-2023 | Breztri |
| Allergan, INC. | $105.81 | 2019-2020 | |
| Amarin Pharma, INC. | $102.52 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.04 | 2019-2020 | |
| Bausch Health US, LLC | $74.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.66 | 2021 | |
| Lilly USA, LLC | $58.70 | 2019-2021 | |
| Antares Pharma, INC. | $48.59 | 2019 | |
| Eisai INC. | $40.96 | 2019-2021 | |
| Indivior INC. | $40.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.42 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $36.74 | 2019 | |
| Mdd US Operations, LLC | $31.57 | 2019 | |
| Verona Pharma, INC. | $27.64 | 2025 | Ohtuvayre |
| Medline Industries LP | $26.70 | 2019 | |
| Pfizer INC. | $22.85 | 2024 | |
| Invivyd INC | $20.85 | 2025 | Pemgarda |
| Amgen INC. | $20.54 | 2019 | |
| Endo Pharmaceuticals INC. | $20.09 | 2019 | |
| Biodelivery Sciences International, INC. | $19.63 | 2021 | |
| Genentech USA, INC. | $19.47 | 2019 | |
| Vivus LLC | $18.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.08 | 2019 | |
| Shire North American Group INC | $13.30 | 2019 | |
| Currax Pharmaceuticals LLC | $13.04 | 2019 | |
| Seqirus USA INC | $12.76 | 2019 | |
| Biofire Diagnostics, LLC | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.